Major depression, because of its recurring and life-threatening nature, is one of the top 10 diseases for global disease burden. Major depression is still diagnosed on the basis of clinical symptoms in patients. The search for specific biological markers is of great importance to advance the method of diagnosis for depression. We examined the methylation profile of 2 CpG islands (I and IV) at the promoters of the brain-derived neurotrophic factor (BDNF) gene, which is well known to be involved in the pathophysiology of depression. We analyzed genomic DNA from peripheral blood of 20 Japanese patients with major depression and 18 healthy controls to identify an appropriate epigenetic biomarker to aid in the establishment of an objective system for the diagnosis of depression. Methylation rates at each CpG unit was measured using a MassArray？ system (SEQUENOM), and 2-dimensional hierarchical clustering analyses were undertaken to determine the validity of these methylation profiles as a diagnostic biomarker. Analyses of the dendrogram from methylation profiles of CpG I, but not IV, demonstrated that classification of healthy controls and patients at the first branch completely matched the clinical diagnosis. Despite the small number of subjects, our results indicate that classification based on the DNA methylation profiles of CpG I of the BDNF gene may be a valuable diagnostic biomarker for major depression.
References
[1]
Lopez AD, Mathers CD, Ezzati M, Jamison DT, Murray CJ (2006) Global and regional burden of disease and risk factors, 2001: systematic analysis of population health data. Lancet 367: 1747–1757.
[2]
Murray CJ, Lopez AD (1997) Alternative projections of mortality and disability by cause 1990–2020: Global Burden of Disease Study. Lancet 349: 1498–1504.
[3]
Simon GE, Fleck M, Lucas R, Bushnell DM (2004) Prevalence and predictors of depression treatment in an international primary care study. Am J Psychiatry 161: 1626–1634.
[4]
Chang SM, Hahm BJ, Lee JY, Shin MS, Jeon HJ, et al. (2008) Cross-national difference in the prevalence of depression caused by the diagnostic threshold. J Affect Disord 106: 159–167.
[5]
Cross-national comparisons. Cross-National Collaborative Group (1992) The changing rate of major depression. JAMA 268: 3098–3105.
[6]
Simon GE, Goldberg DP, Von Korff M, Ustun TB (2002) Understanding cross-national differences in depression prevalence. Psychol Med 32: 585–594.
[7]
Weissman MM, Bland RC, Canino GJ, Faravelli C, Greenwald S, et al. (1996) Cross-national epidemiology of major depression and bipolar disorder. JAMA 276: 293–299.
[8]
Carroll BJ, Feinberg M, Greden JF, Tarika J, Albala AA, et al. (1981) A specific laboratory test for the diagnosis of melancholia. Standardization, validation, and clinical utility. Arch Gen Psychiatry 38: 15–22.
[9]
Carroll BJ (1982) The dexamethasone suppression test for melancholia. Br J Psychiatry 140: 292–304.
[10]
Heuser I, Yassouridis A, Holsboer F (1994) The combined dexamethasone/CRH test: a refined laboratory test for psychiatric disorders. J Psychiatr Res 28: 341–356.
[11]
Mossner R, Mikova O, Koutsilieri E, Saoud M, Ehlis AC, et al. (2007) Consensus paper of the WFSBP Task Force on Biological Markers: biological markers in depression. World J Biol Psychiatry 8: 141–174.
[12]
Shimizu E, Hashimoto K, Okamura N, Koike K, Komatsu N, et al. (2003) Alterations of serum levels of brain-derived neurotrophic factor (BDNF) in depressed patients with or without antidepressants. Biol Psychiatry 54: 70–75.
[13]
Sen S, Duman R, Sanacora G (2008) Serum brain-derived neurotrophic factor, depression, and antidepressant medications: meta-analyses and implications. Biol Psychiatry 64: 527–532.
[14]
Hashimoto K (2010) Brain-derived neurotrophic factor as a biomarker for mood disorders: an historical overview and future directions. Psychiatry Clin Neurosci 64: 341–357.
[15]
Simon R (2005) Roadmap for developing and validating therapeutically relevant genomic classifiers. J Clin Oncol 23: 7332–7341.
[16]
Yoo CB, Jones PA (2006) Epigenetic therapy of cancer: past, present and future. Nat Rev Drug Discov 5: 37–50.
[17]
van Vliet J, Oates NA, Whitelaw E (2007) Epigenetic mechanisms in the context of complex diseases. Cell Mol Life Sci 64: 1531–1538.
[18]
Tost J (2010) DNA methylation: an introduction to the biology and the disease-associated changes of a promising biomarker. Mol Biotechnol 44: 71–81.
[19]
Ushijima T (2005) Detection and interpretation of altered methylation patterns in cancer cells. Nat Rev Cancer 5: 223–231.
[20]
Rutten BP, Mill J (2009) Epigenetic mediation of environmental influences in major psychotic disorders. Schizophr Bull 35: 1045–1056.
[21]
Tsankova NM, Berton O, Renthal W, Kumar A, Neve RL, et al. (2006) Sustained hippocampal chromatin regulation in a mouse model of depression and antidepressant action. Nat Neurosci 9: 519–525.
[22]
Chen WG, Chang Q, Lin Y, Meissner A, West AE, et al. (2003) Derepression of BDNF transcription involves calcium-dependent phosphorylation of MeCP2. Science 302: 885–889.
[23]
Martinowich K, Hattori D, Wu H, Fouse S, He F, et al. (2003) DNA methylation-related chromatin remodeling in activity-dependent BDNF gene regulation. Science 302: 890–893.
[24]
Otsubo T, Tanaka K, Koda R, Shinoda J, Sano N, et al. (2005) Reliability and validity of Japanese version of the Mini-International Neuropsychiatric Interview. Psychiatry Clin Neurosci 59: 517–526.
[25]
Sheehan DV, Lecrubier Y, Sheehan KH, Amorim P, Janavs J, et al. (1998) The Mini-International Neuropsychiatric Interview (M.I.N.I.): the development and validation of a structured diagnostic psychiatric interview for DSM-IV and ICD-10. J Clin Psychiatry 59: Suppl 2022–33;quiz 34–57.
[26]
Sengupta PK, Smith BD (1998) Methylation in the initiation region of the first exon suppresses collagen pro-alpha2(I) gene transcription. Biochim Biophys Acta 1443: 75–89.
[27]
Delgado MD, Leon J (2006) Gene expression regulation and cancer. Clin Transl Oncol 8: 780–787.
[28]
Yasuda S, Liang MH, Marinova Z, Yahyavi A, Chuang DM (2009) The mood stabilizers lithium and valproate selectively activate the promoter IV of brain-derived neurotrophic factor in neurons. Mol Psychiatry 14: 51–59.
[29]
Keller S, Sarchiapone M, Zarrilli F, Videtic A, Ferraro A, et al. (2010) Increased BDNF promoter methylation in the Wernicke area of suicide subjects. Arch Gen Psychiatry 67: 258–267.
[30]
Chertkow Y, Weinreb O, Youdim MB, Silver H (2007) Gene expression changes in peripheral mononuclear cells from schizophrenic patients treated with a combination of antipsychotic with fluvoxamine. Prog Neuropsychopharmacol Biol Psychiatry 31: 1356–1362.
[31]
Glatt SJ, Everall IP, Kremen WS, Corbeil J, Sasik R, et al. (2005) Comparative gene expression analysis of blood and brain provides concurrent validation of SELENBP1 up-regulation in schizophrenia. Proc Natl Acad Sci U S A 102: 15533–15538.
[32]
Salisbury BA, Pungliya M, Choi JY, Jiang R, Sun XJ, et al. (2003) SNP and haplotype variation in the human genome. Mutat Res 526: 53–61.
